Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) EBIT Margin (2019 - 2025)

Silo Pharma (SILO) has disclosed EBIT Margin for 7 consecutive years, with 13227.81% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 10912.0% to 13227.81% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1539.06% through Dec 2025, down 86193.0% year-over-year, with the annual reading at 1539.06% for FY2025, 86193.0% down from the prior year.
  • EBIT Margin hit 13227.81% in Q4 2025 for Silo Pharma, up from 6388.16% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 574643.9% in Q4 2021 to a low of 6926.77% in Q2 2025.
  • Historically, EBIT Margin has averaged 31783.01% across 5 years, with a median of 4374.03% in 2023.
  • Biggest five-year swings in EBIT Margin: soared 57025009bps in 2021 and later crashed -56826477bps in 2022.
  • Year by year, EBIT Margin stood at 574643.9% in 2021, then plummeted by -99bps to 6379.13% in 2022, then plummeted by -201bps to 6455.81% in 2023, then skyrocketed by 307bps to 13336.93% in 2024, then fell by -1bps to 13227.81% in 2025.
  • Business Quant data shows EBIT Margin for SILO at 13227.81% in Q4 2025, 6388.16% in Q3 2025, and 6926.77% in Q2 2025.